ModernaVerified account

@moderna_tx

Working to deliver on the promise of mRNA science to create a new class of transformative medicines for patients.

Cambridge, MA
modernatx.com
Joined December 2013
577 Photos and videos Photos and videos

Tweets

You blocked @moderna_tx

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @moderna_tx

  1. Pinned Tweet
    22 hours ago

    Did you know that is the number 1 infection that causes birth defects in the US? June is month & we are committed to raising awareness of to help break the silence. Learn more here:

    4 replies 9 retweets 52 likes
    Undo
  2. Jun 2

    Today, we announced an agreement with for a new production line at Lonza’s Geleen Netherlands site, contributing to the supply of an additional 300 million doses of our booster variant vaccine candidate, if authorized, per year, at a 50 µg dose

    9 replies 51 retweets 156 likes
    Undo
  3. Jun 1

    Earlier today, we announced that we have entered into an agreement with Thermo Fisher Scientific for fill/finish sterile manufacturing services and supply packaging for our COVID-19 vaccine. Read more:

    6 replies 28 retweets 141 likes
    Undo
  4. Jun 1

    This morning, we announced that we have initiated the rolling submission process for a Biologics License Application (BLA) with the U.S. FDA for our COVID-19 vaccine. Read more:

    7 replies 47 retweets 167 likes
    Undo
  5. May 27

    Moderna scientists are targeting hematopoietic stem and progenitor cells in the bone marrow to modulate inflammation and immune diseases

    9 replies 20 retweets 99 likes
    Undo
  6. May 27

    Many considerations are taken in to account in order to deliver our medicines and vaccines

    4 replies 11 retweets 83 likes
    Undo
  7. May 27

    We are continuing to unlock science to develop transformative mRNA medicines

    1 reply 25 retweets 117 likes
    Undo
  8. May 27

    Moderna is building a highly efficient, data driven and reliable system to identify SARS-CoV-2 variants of concern

    9 replies 54 retweets 218 likes
    Undo
  9. May 27

    Our current SARS-CoV-2 variant booster candidate selection process

    5 replies 31 retweets 159 likes
    Undo
  10. May 27

    Moderna's platform technologies. Melissa J. Moore, our Chief Scientific Officer of Platform Research is presenting now at Science Day

    3 replies 14 retweets 51 likes
    Undo
  11. May 27

    Our commitment to be the best at science is core to who we are. This is just the beginning.

    6 replies 17 retweets 113 likes
    Undo
  12. May 27

    We are a leading platform and continue to invest like it’s the beginning of the journey

    2 replies 17 retweets 82 likes
    Undo
  13. May 27

    Join us for Science Day happening now:

    2 replies 13 retweets 71 likes
    Undo
  14. May 27

    Today, at our 4th annual Science Day, we will highlight new research to provide insight into the diverse efforts underway at Moderna to better understand how to use mRNA as medicines & vaccines. Read more & join us at 8am ET:

    3 replies 12 retweets 75 likes
    Undo
  15. May 25

    We just announced that the Phase 2/3 study of our COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint. In the study, no cases of COVID-19 were observed in participants who had received 2 doses of the vaccine:

    30 replies 249 retweets 789 likes
    Undo
  16. May 24

    We just announced an expanded collaboration with in support of the Moderna COVID-19 Vaccine and additional programs in our clinical development pipeline. Read more:

    11 replies 15 retweets 142 likes
    Undo
  17. May 22

    We just announced two Memoranda of Understanding with South Korea. We will explore potential areas of collaboration for research and development of mRNA vaccines and local manufacturing opportunities in South Korea. Read more:

    21 replies 112 retweets 212 likes
    Undo
  18. May 21

    Important peer-reviewed work by Prof Miles P. Davenport, et al. on the duration of neutralizing antibodies & role of SARS-CoV-2 variants published in Read the manuscript: . We were honored to have Prof Davenport present at our Vaccines Day!

    8 replies 11 retweets 77 likes
    Undo
  19. May 21

    This morning we announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved our application for Conditional Marketing Authorization for our mRNA vaccine against COVID-19. Read more:

    16 replies 29 retweets 147 likes
    Undo
  20. May 21

    We continue to scale our commercial network. We are pleased to announce that our commercial subsidiary in Japan, Moderna K.K., was incorporated in April 2021 and we are actively hiring locally.

    5 replies 13 retweets 69 likes
    Undo

@moderna_tx hasn't Tweeted yet.

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·